Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse

Environmental Health Perspectives

Volumn 111, Issue 6, 2003, Pages 855-861

  Smith, Andrew G ^a   Davies, Reginald ^a   Dalton, Timothy P ^b   Miller, Marian L ^b   Judah, David ^a   Riley, Joan ^a   Gant, Timothy ^a   Nebert, Daniel W ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

cDNA expression library; Cell cycle control; Cholesterol biosynthesis; Cyp1a2( ) knockout mouse; CYP1A2, endogenous substrate metabolism; CYP1A2, foreign chemical metabolism; Fatty acid biosynthesis; Insulin action; Lipogenesis

Indexed keywords

BILE ACID; CAFFEINE; CARCINOGEN; CHOLESTEROL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; ESTRADIOL; FATTY ACID; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INSULIN; LIPID; MELATONIN; PHENACETIN; SOMATOMEDIN BINDING PROTEIN 1; STEROID; STEROL; UROPORPHYRINOGEN; ZOXAZOLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CARCINOGENESIS; CELL CYCLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIETARY INTAKE; DNA MICROARRAY; DOWN REGULATION; DRUG METABOLISM; FATTY ACID SYNTHESIS; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HORMONE ACTION; INTERSTITIUM; KNOCKOUT MOUSE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; PHENOTYPE; PLANT; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROID HYDROXYLATION; STEROID METABOLISM; STEROL METABOLISM; UPREGULATION; WILD TYPE;

ANIMALIA; EUKARYOTA;

EID: 0037838823     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.111-1241507     Document Type: Article

References (39)

1. Akhtar RA, Reddy AB, Maywood ES, Clayton JD, King VM, Smith AG, et al. 2002. Circadian cycling of the mouse liver transcriptome, as revealed by cDNA microarray, is driven by the suprachiasmatic nucleus. Curr Biol 12:540-550.
2. Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ. 1996. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 6:291-296.
3. Camus-Randon AM, Raffalli F, Bereziat JC, McGregor D, Konstandi M, Lang MA. 1996. Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic-metabolizing CYP enzymes. Toxicol Appl Pharmacol 138:140-148.
4. Dalton TP, Dieter MZ, Matlib RS, Childs NL, Shertzer HG, Genter ME, et al. 2000a. Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 267:184-189.
5. Dalton TP, Miller ML, Wu X, Menon A, Cianciolo E, McKinnon RA, et al. 2000b. Refining the mouse chromosomal location of Cdm, the major gene associated with susceptibility to cadmium-induced testicular necrosis. Pharmacogenetics 10:141-151.
6. DeRisi JL, Iyer VR, Brown PO. 1997. Exploring the metabolic and genetic control of gone expression on a genomic scale. Science 278:680-686.
7. Dorne JL, Walton K, Renwick AG. 2001. Uncertainty factors for chemical risk assessment. Human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem Toxicol 39:681-696.
8. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. 1995. Role of cytochrome P450 1A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
9. Eisen MB, Brown PO. 1999. DNA arrays for analysis of gene expression. Meth Enzymol 303:179-205.
10. Fornace AJ Jr, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, et al. 1989. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 9:4196-4203.
11. Heilmann LJ, Sheen YY, Bigelow SW, Nebert DW. 1988. The trout P450 IA1. ONA and deduced protein sequence, expression in liver, and evolutionary significance. DNA 7:379-387.
12. Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD, Haines DC, et al. 2001. Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res 61:2487-2491.
13. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. 2002. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277:11019-11025.
14. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, et al. 1999. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice Carcinogenesis 20:1825-1830.
15. Lavery DJ, Lopez-Molina L, Margueron R, Fleury-Olela F, Conquet F, et al. 1999. Circadian expression of the steroid 15α-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine-zipper transcription factor DBP. Mol Cell Biol 19:6488-6499.
16. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. 1997. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and α-tocopherol. Pharmacogenetics 7:11-19.
17. Liang HC, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, et al. 1996. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci U S A 93:1671-1676.
18. Liang HC, McKinnon RA, Nebert DW. 1997. Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same in Cyp1a2(+/+) wild-type and Cyp1a2(-/-) null mutant mice. Biochem Pharmacol 54:1127-1131.
19. Nebert DW. 1997. Polymorphisms in drug-metabolizing enzymes: what is their clinical significance and why do they exist? Am J Hum Genet 60:265-271.
20. Nebert DW, Dalton TP, Stuart GW, Carvan MJ III. 2000a. "Gene-swap knock-in" cassette in mice to study allelic differences in human genes. Ann NY Acad Sci 919:148-170.
21. Nebert DW, Dieter MZ. 2000. The evolution of drug metabolism. Pharmacology 61:124-135.
22. Nebert DW, Duffy JJ. 1997. How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem Pharmacol 53:249-254.
23. Nebert DW, McKinnon RA, Puga A. 1996. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280.
24. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, et al. 1991. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10:1-14.
25. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. 2000b. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59:65-85.
26. Nebert DW, Russell DW. 2002. Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
27. Negishi M, Lindberg R, Burkhart B, Ichikawa T, Honkakoski P, Lang M. 1989. Mouse steroid 15α-hydroxylase gene family: identification of type II P-450(15α) as coumarin 7-hydroxylase. Biochemistry 28:4169-4172.
28. Pelkonen O. 2002. Cross-talk between signal transduction systems and cytochrome P450 regulation. Pharmacologist 44(2) (suppl 1):A142.
29. Peters JM, Morishima H, Ward JM, Coakley CJ, Kimura S, Gonzalez FJ. 1999. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol Sci 50:82-89.
30. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, Gonzalez FJ. 1995. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci U S A 92:5134-5138.
31. Shertzer HG, Dalton TP, Talaska G, Nebert DW. 2002. Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol Appl Pharmacol 181:32-37.
32. Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, et al. 1998. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J 330:149-153.
33. Sinclair PR, Gorman N, Walton HS, Bement WJ, Dalton TP, Sinclair JF, et al. 2000. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 162:60-67.
34. Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, et al. 2001. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 173:89-98.
35. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, et al. 2001. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20:1300-1306.
36. van der Lugt N, Maandag ER, te Riele H, Laird PW, Berns A. 1991. A pgk::hprt fusion as a selectable marker for targeting of genes in mouse embryonic stem cells: disruption of the T-cell receptor δ-chain-encoding gene. Gene 105:263-267.
37. Wastl UM, Rossmanith W, Lang MA, Camus-Randon AM, Grasl-Kraupp B, Bursch W, et al. 1998. Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions. Mol Carcinog 22:229-234.
38. Yeagley D, Guo S, Unterman T, Quinn PG. 2001. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. J Biol Chem 276:33705-33710.
39. Zaccaro C, Sweitzer S, Pipino S, Gorman N, Sinclair PR, Sinclair JF, et al. 2001. Role of cytochrome P450 1A2 in bilirubin degradation. studies in Cyp1a2(-/-) mutant mice. Biochem Pharmacol 61:843-849.